FDA approves Exact Sciences' improved stool-based colon cancer test

Plus: Chinese biopharma's cancer therapies

October 8, 2024 Check out STAT+

Sponsored By

Wikimedia Commons STAT+ | Exact Sciences wins FDA approval for improved stool-based colon cancer test The new Cologuard Plus screening test should result in fewer cancer-free patients receiving unnecessary follow-up colonoscopies By Jonathan Wosen 2024 Nobel prize in medicine: Ruvkun, Ambros win for discovery of microRNA The prize went to the two researchers for their discovery of microRNA, which plays a crucial role in regulating gene activity. By Andrew Joseph STAT+ | 12 people changing the course of the Chinese biopharma industry STAT profile series on key players in life sciences looks at the 12 top players in Chinese biotechnology, from researchers to pharma corporate executives. By Brian Yang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser